Physician profile
Anna Grace Buck
NPI 1174278667
$4,310.33
in general payments reported to CMS, 2019-2025
23 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,130 · 2024: $1,901 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,135 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,135.35 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $719.49 | 2023-2025 | |
| Abbvie INC. | $477.53 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $421.22 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $413.67 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $412.83 | 2023-2025 | Sotyktu |
| Acumed LLC | $317.27 | 2023 | Acumed, Osteomed |
| Incyte Corporation | $257.87 | 2023-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $174.98 | 2023-2024 | |
| Biofrontera INC. | $144.77 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $136.60 | 2023-2024 | |
| Lilly USA, LLC | $103.64 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $99.20 | 2023-2025 | Zoryve |
| Ucb, INC. | $90.15 | 2023-2024 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $87.49 | 2023-2025 | Aklief, Epsolay, Oracea |
| Leo Pharma INC. | $83.00 | 2025 | Anzupgo, Adbry |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $79.44 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $73.88 | 2024-2025 | |
| Janssen Biotech, INC. | $53.76 | 2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.84 | 2023-2025 | Cabtreo, Arazlo |
| Medimetriks Pharmaceuticals, INC. | $36.52 | 2025 | Neo-Synalar, Clindacin Etz |
| Convatec INC. | $36.02 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.12 | 2024 | Spevigo |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.